Vape pens marketed as cannabis are being laced with potent synthetic opioids like nitazenes. The DEA has confirmed at least 17 nitazene variants are active in the U.S., many of which are undetectable ...

It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Novo Nordisk's potential layoffs come as the pharmaceutical major, which has developed the weight-loss drug Wegovy, seeks to reduce costs amid a fierce battle with Eli Lilly for the weight-loss drug ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Novo Nordisk A/S agreed to buy Akero Therapeutics Inc. for as much as $5.2 billion to expand its portfolio in a type of liver disease that’s linked to obesity. Novo will pay $54 a share in cash, ...

Novo Nordisk's acquisition of Akero Therapeutics includes efruxifermin, a potential best-in-class treatment for MASH, aligning with its strategy to address diabetes and obesity-related comorbidities.